

STOP Counterfeits!
And Increase Your Market Share!

Like :-

Indian corporates lose **21.7%** of their sales to counterfeits!*

All Copyrights acknowledged *Source PICCO

Brand Rakshak Mr. Rohit D. Mistry
9820011569
www.holtechtis.com

Published by :



DAY 3

News ATA GLANCE



India needs to focus on complex generics, biosimilars to reach...

▶ Page No. 4



Govt handholding needed to reduce API manufacturing...

▶ Page No. 8



Regulatory approval process in India needs to be streamlined...

▶ Page No. 26

Commerce ministry calls on pharma MSMEs to invest in Africa to seize growth opportunities

LAXMI YADAV, MUMBAI

THE Union Ministry of Commerce and Industry has called on pharmaceutical micro, small and medium enterprises (MSMEs) to invest in Africa, citing its potential as a significant growth market and a potential for collaboration.

Indian companies account for around 20% of Africa's pharmaceutical exports. This makes India a key player in Africa's healthcare system, and the country's exports help to ensure the availability of affordable medicines.

Addressing an industry meet on the sidelines of the 10th International Exhibition for Pharma and Healthcare

(IPHEX) on August 29, 2024, commerce secretary Sunil Barthwal said "Africa is currently an emerging market, it has the potential to become a significant growth market." He urged the industry to consider investing in Africa, as the region is increasingly looking to India for collaboration.

He advised industry against limiting

CONTINUED ON p2▶






CELLULOSE RANGE

HPMC
(Hypromellose)

L-HPC

Methyl Cellulose



The **right ingredient** can make all the difference in your formulations

Talk to us
for more information

101-103, Shyam Kamal 'D', Agarwal Market, Vile Parle (E), Mumbai - 400 057, India
Tel: +91-22-45212000 | Email: products@pioma.net

Vital Trends Shaping the Future of the Indian Drug Industry in 2024



DR. SANJAY AGRAWAL

THE Indian pharmaceutical industry, a global powerhouse in drug production and export, is experiencing a transformative phase in 2024. With its dynamic landscape influenced by various factors, the sector is evolving to meet new challenges and opportunities. Here, we explore the vital trends shaping the future of the Indian drug industry, from technological advancements and regulatory shifts to market demands and sustainability.

1. Digital Transformation and Technological Advancements

The integration of digital technologies is revolutionizing the Indian drug industry. Key trends in this domain include:

a. Artificial Intelligence (AI) and Machine Learning (ML): AI and ML are increasingly being used to streamline drug discovery, development, and manufacturing processes. AI algorithms can analyze vast datasets to identify potential drug candidates and predict their efficacy, significantly reducing the time and cost associated with research and development (R&D). In 2024, we are seeing a surge in AI-powered platforms that enhance drug formulation, optimize clinical trials, and personalize treatments based on patient data.

b. Blockchain Technology: Blockchain is gaining traction for its potential to ensure transparency and traceability in the pharmaceutical supply chain. By securely recording every transaction and movement of drugs, blockchain helps in combating counterfeit drugs, ensuring product authenticity, and enhancing regulatory compliance.

c. Internet of Medical Things (IoMT): IoMT devices, including wearable health monitors and smart medical equipment, are becoming more prevalent. These devices provide real-time health data, enabling better patient monitoring and personalized medication regimens. The

growth of IoMT is driving the development of new drug delivery systems and enhancing patient outcomes.

2. Regulatory and Compliance Changes

Regulatory frameworks are evolving to address new challenges and improve drug safety and efficacy. Key regulatory trends include:

a. Enhanced Drug Approval Processes: The Central Drugs Standard Control Organization (CDSCO) is adopting more streamlined processes for drug approvals to accelerate the availability of new medications. In response to the global demand for faster drug delivery, there is an emphasis on expediting the approval of innovative drugs and generics.

b. Focus on Quality Assurance: There is a growing emphasis on quality assurance and adherence to Good Manufacturing Practices (GMP). The industry is witnessing stricter enforcement of quality standards to ensure the safety and efficacy of pharmaceutical products. Companies are investing in advanced quality control technologies and processes to meet these rigorous standards.

c. Data Privacy and Security Regulations: With the rise of digital health solutions and patient data collection, there is an increasing focus on data privacy and security. The implementation of stringent data protection regulations, such as the Personal Data Protection Bill, aims to safeguard patient information and ensure ethical handling of data.

3. Market Dynamics and Demand Shifts

The Indian drug industry is responding to changing market demands and evolving consumer preferences. Key trends in this area include:

a. Growth of Generic and Biosimilars Market: India remains a leading player in the global generic drugs market, and the demand for affordable medications continues to rise. The biosimilars market is also expanding as more biosimilars receive regulatory approvals. Companies are investing in R&D to develop high-quality biosimilars that offer cost-effective alternatives to biologic drugs.

b. Focus on Chronic and Lifestyle Diseases: With the increasing prevalence of chronic and lifestyle-related diseases such as

diabetes, cardiovascular diseases, and obesity, there is a growing demand for innovative treatments and preventive measures. Pharmaceutical companies are developing new drugs and therapies to address these health issues, catering to the evolving needs of the population.

c. Expansion of Over-the-Counter (OTC) Market: The OTC drug market is witnessing significant growth as consumers seek convenient and accessible healthcare solutions. The expansion of online pharmacies and e-commerce platforms is driving the availability of OTC products, making it easier for consumers to access medications and health supplements.

4. Sustainability and Green Manufacturing

Sustainability is becoming a critical focus in the pharmaceutical industry. Key

trends in this area include:

a. Green Chemistry and Eco-friendly Practices: There is a growing emphasis on green chemistry principles and sustainable manufacturing practices. Pharmaceutical companies are adopting eco-friendly methods to reduce their environmental footprint, such as minimizing waste, optimizing energy consumption, and using renewable resources.

b. Circular Economy Initiatives: The concept of a circular economy, which focuses on reusing and recycling materials, is gaining traction in the pharmaceutical industry. Companies are exploring ways to recycle packaging materials, reduce plastic usage, and implement closed-loop systems to minimize environmental impact.

CONTINUED ON p33▶

"Working Today for Healthier Tomorrow"

API PRODUCT LIST

<ul style="list-style-type: none"> • Acenocoumarol • Amlodipine Besylate • Amphotericin B Injection Grade • Avanaflil • Azithromycin Dihydrate • Chloramphenicol • Chloramphenicol Palmitate • Clarithromycin • Dapoxetine Hcl • Empagliflozin • Erythromycin • Erythromycin Estolate • Erythromycin Ethyl Succinate • Erythromycin Phosphate • Erythromycin Stearate • Etomidate • Flibensarin • Fluphenazine Decanoate • Fluticasone Propionate • Gramicidin 	<ul style="list-style-type: none"> • Linagliptin • Molnupiravir • Nirmatrelvir * New Drug • Ofloxacin • Oxytetracycline Dihydrate (Inj Grade) • Oxytetracycline Hcl (inj Grade) • Palonosetron Hcl • Phenyl Butazone • Pregabalin • Rosuvastatin Calcium • Roxithromycin • Sevelamer Carbonate • Sevelamer Hydrochloride • Sildenafil Citrate • Sitagliptin Phosphate Monohydrate • Sofosbuvir • Tadalafil • Tetracycline Hcl • Tiapride 	<ul style="list-style-type: none"> • Vardenafil Hcl Trihydrate • Vildagliptin <p>Vit D Derivatives</p> <ul style="list-style-type: none"> • Calcitriol • Alfacalcidol • Calcipotriol <p>Anti Glaucoma</p> <ul style="list-style-type: none"> • Bimatoprost • Carboxiprost Tromethamine • Latanoprost • Latanoprostene Bunod • Misoprostol • Nor Bimatoprost • Tafluprost • Travoprost <p>Ophthalmic</p> <ul style="list-style-type: none"> • Dorzolamide Hcl • Brinzolamide
--	---	---

Century Pharmaceuticals Ltd.

Corporate address:
406, World Trade Center, Soyajiganj, Vadodara, India 390005
Ph - +91 265 2361581/2361978/2362509
Fax - +91 265 2226023
Email - info@centurypharma.com
infocenturypharma@gmail.com

Site address:
103-106, GIDC, Halol, Dist. Panchmahals - 389350
Ph. +91 2676 220912

Vital Trends Shaping the Future...

CONTINUED FROM p31▶

c. Corporate Social Responsibility (CSR): Companies are increasingly incorporating CSR initiatives into their business strategies. This includes supporting community health programs, enhancing access to medicines in underserved areas, and investing in sustainable development projects.

5. Globalization and International Collaboration

The Indian pharmaceutical industry is expanding its global footprint through international collaborations and market diversification. Key trends include:

a. Strategic Partnerships and Alliances: Indian pharmaceutical companies are forming strategic partnerships with global players to enhance their R&D capabilities, expand market reach, and gain access to advanced technologies. Collaborations with international research institutions and biotech firms are fostering innovation and driving growth.

b. Expansion into Emerging Markets: Indian drug manufacturers are exploring opportunities in emerging markets with growing healthcare needs. The expansion into regions such as Africa, Latin America, and Southeast Asia presents new avenues for growth and market penetration.

c. Compliance with Global Standards: To compete on a global scale, Indian pharmaceutical companies are aligning their operations with international quality standards and regulatory requirements. This includes obtaining certifications from global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

6. Personalized Medicine and Precision Healthcare

The shift towards personalized medicine and precision healthcare is reshaping the Indian drug industry. Key trends include:

a. Genetic and Genomic Research: Advances in genetic and genomic research are enabling the development of targeted therapies tailored to individual patients. By understanding genetic variations and their impact on drug response, pharmaceutical companies can create personalized treatment plans that improve efficacy and reduce adverse effects.

b. Tailored Drug Delivery Systems: The development of personalized drug delivery systems, such as customized dosage forms and drug combinations, is enhancing treatment outcomes. Companies are investing in technologies that allow for precise drug delivery based on

patient-specific factors, such as genetic profile and disease characteristics.

c. Integration of Big Data: The integration of big data analytics in healthcare is providing valuable insights into patient populations and treatment patterns. By analyzing large datasets, companies can identify trends, predict disease outbreaks, and develop targeted interventions.

Drive Growth with AI and Analytics in Pharma Industry

Pharmaceutical companies can significantly boost their growth by accelerating processes across the value chain, from drug development to market entry. This requires a bold and responsible adoption of AI and analytics, tapping into their transformative potential. AI and generative AI (GenAI) offer valuable opportunities across various stages of the pharmaceutical journey, including drug discovery, clinical trial design, medical writing, promotional content, and customer engagement. In fact, there are over 200 potential applications of GenAI that could profoundly impact pharmaceutical operations.

This is not about embracing technology for its own sake but about leveraging digital tools to enhance speed, connectivity, and efficiency. According to the research by an MNC, AI-enabled automation and advanced analytics can deliver substantial benefits:

- **60% to 70% Reduction in Process Timelines:** Thanks to real-time intervention in clinical trials, optimized supply chains, and data-driven decision-making that can systematize and automate institutional knowledge.

- **Decreased Burden on Patients, Providers, and Companies:** Through operational efficiencies and AI-assisted decision-making, reducing strain across the entire ecosystem of healthcare and pharmaceutical professionals.

- **30% or Greater Reduction in Operational Costs:** Driven by enhanced efficiency through content automation, better data quality, and streamlined processing.

- **40% or More Reduction in Project Delivery Timelines:** Transforming IT from a mere enabler to an active digital partner, enabling rapid prototyping and deployment.

To harness the power of next-generation technology, leaders should focus on:

- **A Clear Vision:** Define how and where they will leverage advanced technology to unlock value, setting measurable objectives and understanding its implications for future roles and skills.

- **A Responsibility Framework:** Develop practices for the ethical use of AI to build trust with stakeholders.

- **An Ambitious Use Case Portfolio:** Similar to drug development, include projects with high transformative potential and maintain strong program management to transition from concept to implementation.

- **A Scalable Infrastructure:** Build or partner with a robust system capable of scaling to meet evolving needs.

Investing in AI, data analytics, and machine learning will enable companies to accelerate drug development, improve efficiency, and achieve faster market uptake. Embracing these technologies is crucial for staying competitive and realizing significant gains across the phar-

maceutical value chain.

Conclusion

As the Indian drug industry navigates through 2024, it is clear that several vital trends are shaping its future. The integration of digital technologies, evolving regulatory frameworks, shifting market demands, and a focus on sustainability are driving the industry's growth and transformation. With a growing emphasis on innovation, global collaboration, and personalized medicine, the Indian pharmaceutical sector is poised to continue its trajectory as a leading global player in drug development and manufacturing. As the industry adapts to these trends, it will play a crucial role in addressing global healthcare challenges and improving patient outcomes.

(Author is the Leading Pharmaceutical Consultant and Editor-in-Chief of UMToday)

USFDA REGISTERED
(Ramdev Plaza, Mira Road (East))

NABL ACCREDITED LAB
(Kandivali (West), Mumbai)

MANISHA ANALYTICAL LABORATORIES PVT. LTD.
GOVT. APPROVED TECHNICAL ANALYSTS
QUALITY ASSURANCE & PROMPT SERVICES

Our Testing Facility

LAB OVERVIEW

LC-MS/MS

HPLC FACILITY

GC CHROMATOGRAPH

DISSOLUTION FACILITY

WALK-IN STABILITY CHAMBERS

Method Development, Method validation, Process Validation, Impurity Characterization & Profile, Dissolution Profile, Residual Solvents & Stability Study

R&D Lab
401, 402 & 601, 602, Ramdev Plaza, Kashigaon, Mira Road (East), Dist.Thane - 401 107
Email : info@manishalab.com

Lab
135-A, Govt. Indl Estate, Charkop, Kandivali (W), Mumbai - 400 067, Tel.: 022-67749888 (30 Lines)
Email : tech@manishalab.com www.manishalab.com